Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

Speakers from the Muscular Dystrophy Association (MDA) highlighted 75 years of progress in understanding and treating ...

A collection of scientists, all pursuing breakthroughs in their fields, and top administrators, held a roundtable discussion ...

The World Society of Pediatric Ophthalmologists recognizes the value of controlling ... Myopia is therefore being seen as a public health issue and a vector of social inequality. Decision-makers ...

Measles is one of the most contagious diseases on Earth. The only way to contain it is vaccination uptake of least 95 per cent. Vaccine hesitancy is at the root of every measles outbreak. What’s at ...

Danon disease is a rare but serious cardiomyopathy that drastically reduces life expectancy. Male patients infrequently live ...

RGX-121 has received Orphan Drug Product, Rare Pediatric Disease ... About RGX-111 RGX-111 is designed to use the AAV9 vector to deliver the α-l-iduronidase (IDUA) gene to the central nervous ...

KARACHI: Thar Foundation has organized career counselling session for students, organizing free medical camp and installing ...